This is the authors' abstract. We don't add key points for this paper.
The in vitro antibacterial activities of several halovinylglycine compounds and their L-norvalyl peptide derivatives are presented. The most potent of them, L-norvalyl-L-chlorovinylglycine, displayed good activity against gram-positive organisms, including methicillin-resistant Staphylococcus species. Chlorovinylglycine is an efficient inhibitor of alanine racemase, but the antibacterial activity of L-norvalyl-L-chlorovinylglycine may involve other physiological targets as well.
No takes yet. Share an insight, caveat, or question.
Patchett et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: